Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 1/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6837437 | 0.88 | — | — | |
| SCHEMBL20456084 | 0.86 | LPL (0.31) | LPLLIPG | |
| SCHEMBL140519 | 0.78 | LPL (0.32) | LPLLIPGP2RX7 | |
| SCHEMBL28578370 | 0.77 | — | — | |
| SCHEMBL24616853 | 0.76 | LPL (0.31) | LPLLIPGP2RX7 | |
| SCHEMBL22861265 | 0.76 | LPL (0.37) | LPLLIPGP2RX7 | |
| SCHEMBL24617151 | 0.76 | CA1 (0.33) | LPLLIPGP2RX7 | |
| SCHEMBL30896150 | 0.76 | FFAR1 (0.33) | LPLLIPGP2RX7 | |
| SCHEMBL20543216 | 0.75 | FFAR1 (0.33) | LPLLIPGP2RX7 | |
| SCHEMBL29403031 | 0.75 | LPL (0.33) | LPLLIPGP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3867248-B1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-12-10 | — | — | EP | disclosed |
| CN-117024411-A | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-110709392-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11447498-B2 | Fused tetracyclic compounds and uses thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-09-20 | — | — | US | disclosed |
| EP-3601259-B1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | HOFFMANN LA ROCHE (CH) | 2022-02-23 | — | — | EP | disclosed |
| US-20220041614-A1 | FUSED TETRACYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-02-10 | — | — | US | disclosed |
| WO-2021113479-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20210163417-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| CN-110964023-A | Fused tetracyclic compounds and application thereof in medicines | 广东东阳光药业有限公司 | 2020-04-07 | — | — | CN | disclosed |
| CN-110709392-A | Isoquinoline as HPK1 inhibitors | 豪夫迈·罗氏有限公司 | 2020-01-17 | — | — | CN | disclosed |
| US-20180282282-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11447498-B2 | Fused tetracyclic compounds and uses thereof in medicine | SLC10A1, CYP4A11, CYP11B2 | LPL 2232/4885LIPG 3664/4885P2RX7 3581/4885 |
| US-20220041614-A1 | FUSED TETRACYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SLC10A1, CYP4A11, CYP11B2 | LPL 2232/4885LIPG 3664/4885P2RX7 3581/4885 |
| US-20180282282-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | HIPK1, HPGDS, IP6K1 | LPL 3043/4885LIPG 2132/4885P2RX7 3767/4885 |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | HIPK1, HIPK2, IP6K1 | LPL 2922/4885LIPG 2923/4885P2RX7 3772/4885 |
| US-20210163417-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | HIPK1, HIPK2, IP6K1 | LPL 2922/4885LIPG 2923/4885P2RX7 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.